 |
|
|
| |
Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Christophe Hezode,1 Nancy Reau,2 Evguenia S. Svarovskaia,3 Brian P. Doehle,3 Krishna Chodavarapu,3 Hadas Dvory-Sobol,3 John McNally,3 Anu Osinusi,3 Diana M. Brainard,3 Michael D. Miller,3 Hongmei Mo,3 Stuart K. Roberts,4 Jacqueline G. O'Leary5
1Universite Paris-Est Creteil Val de Marne, Creteil, France; 2Rush University Medical Center, Chicago, Illinois, USA; 3Gilead Sciences, Inc., Foster City, California, USA; 4Alfred Health and Monash University, Melbourne, Victoria, Australia; 5Baylor University Medical Center at Dallas, Texas, USA
|
| |
|
|
|
|
|
